Introduction
Three questions posed regarding how regulatory/public health agencies consider the biologic effects of low-level exposures are as follows. Short answers to these questions are given here; more detailed discussion follows.
First, does the understanding of the mechanisms of toxicity affect how the agency assesses risks from exposures to toxic substances? Yes, unless specifically precluded from doing so by statute, e.g., the Delaney clause (1) of the Food, Drug, and Cosmetic Act (FDCA). In most cases there are no available data to consider.
Second, does an understanding of the mechanisms by which the body adapts (e.g., detoxifies, repairs, etc.) to the effects of exposures to toxic substances affect how the U.S. Food and Drug Administration (U.S. FDA) assesses risks from exposures to toxic substances? Yes, unless specifically precluded from doing so by statute, e.g., the Delaney clause (1) .
Third, if low doses of toxic agents induce apparently beneficial responses (e.g., enhanced longevity, lower incidence of disease), how does and/or could the U.S. FDA address this? The U.S. FDA is required by law to consider the efficacy of human and animal drugs, biologics, and medical devices. Benefits, except where specifically excluded by statute (e.g., food additives) are considered. It is generally difficult to weigh risks versus benefits.
A brief overview is provided of some of the general safety and risk assessment procedures used by each of the U.S. FDA centers to evaluate low-level exposures of toxic agents in consumer products. Different centers of the U.S. FDA are responsible for the safety of foods and cosmetics, veterinary drugs, medical devices and radiation, human drugs, and biologics.
Center for Food Safety and Applied Nutrition
The Center for Food Safety and Applied Nutrition (CFSAN) is responsible for ensuring the safety of cosmetics and the food supply in two major areas: food additives and natural and anthropogenic environmental contaminants. The legal and regulatory standards in the federal FDCA (2) that apply to these areas allow for the consideration of benefits for environmental contaminants, but may preclude them from consideration for food additives (e.g., prohibition by the Delaney clause) (1) . Even (3) (4) (5) . Often one of the most challenging problems is the determination of the low levels of exposures to leachants.
The CDRH has used risk-assessment methodologies to estimate the risks associated with radiation-emitting products. For example, assessments have been made for malfunctioning diagnostic and therapeutic X-ray machines to determine if there were any significant risks of genetic, carcinogenic, or reproductive health effects. Skin cancer risks have been estimated by the CDRH for ultraviolet-emitting sunlamps, tungsten halogen lamps, and fluorescent lamps. Risk assessments have also been conducted for the potential adverse health effects produced by exposure to microwave and extremely-low-frequency radiation from products such as cellular telephones and police radar systems and for possible adverse health effects of ultrasound diagnostic imaging systems. Based on the mechanisms and experimental data for ionizing radiation, a linear dose response has been used for estimating the risk of leukemia and a linear-quadratic model for solid tumors. For genetic effects from ionizing radiation, exposure limits have been set on the assumption that a small addition to background radiation exposure would be tolerable. For example, the television receiver standard has been set as 5% of natural background radiation exposure to the gonads.
The development of adverse health effects after exposure to microbially contaminated products represents a potentially significant public health concern. The CDRH is collaborating with the National Center for Toxicological Research (NCTR) to develop an approach for characterizing the risk posed by exposure to microbially contaminated medical devices. Specifically, this approach is being developed to provide additional scientific bases for sterility assurance level(s) (SAL) established by the CDRH for devices. An SAL is the probability of at least one microorganism, potentially capable of multiplying and producing infections, existing on a device after it has been submitted to a sterilization process.
Center for Drug Evaluation and Research
The mission of the Center for Drug Evaluation and Research (CDER) is to approve drugs for marketing that are safe, effective, and provide benefits that outweigh their risks. Additionally, the CDER helps ensure that product quality and safety are maintained during marketing.
Risk assessment in the drug approval process is unique because assessments of the risks of a drug are conducted based on actual studies of the drug in humans at levels of exposure likely to be encountered by the population using the drug after approval. The level of exposure in clinical trials is determined on the basis of dose-response and dose-ranging studies designed to estimate the effective dose and conducted in both animals and humans. The risks identified during the controlled clinical trials are evaluated for the general population who will be using the drug. If the benefits of drug therapy exceed the risks, the drug will be approved.
Predinical animal studies are conducted to identify the potential hazards associated with a drug. They provide early approximations of the margin of safety (ratio of toxic dose in animals to the intended human dose) of the drug as well as estimates of efficacy. The primary purpose of animal studies is to identify highly toxic drugs and drugs that are potentially carcinogenic, genotoxic, or reproductive/developmental toxicants. These results are used in the design of future clinical studies to minimize risks of participants. Concern about toxicity depends on the mode of action, efficacy, and duration of drug use. Traditional lowdose extrapolation is rarely used to evaluate the results of preclinical animal studies for drugs. It may be used, for example, to estimate the risk associated with contaminants in drug products in a manner similar to the low-dose methods described earlier.
More commonly, a risk assessment for a drug involves mechanistic data and a weight-of-evidence approach for a qualitative risk/benefit analysis. This approach uses information from preclinical studies and relevant clinical studies to try to determine relevance of the findings for human risk under the proposed conditions of use. The conclusion from such an analysis is then qualitatively factored in with the drug's known clinical characteristics in the approval decision.
Center for Biologics Evaluation and Research
The Center for Biologics Evaluation and Research (CBER) is responsible for protecting and enhancing the public health by ensuring the purity, potency, safety, efficacy, and availability of biologic products. Biologic products indude vaccines, antisera, allergenic extracts, blood, blood products, and blood derivatives.
Biologic products for the most part are complex materials, often derived from living materials from living donors capable of transmitting infectious agents. Thus, they must be closely evaluated and monitored during the production process and in postapproval surveillance to ensure the continued safety and efficacy of the product. Evaluations involve review of source and quality of the starting material, purification, reagents, and contaminants, and include validation of removal or test of residual levels in the final product.
Safety The techniques used for estimating risks associated with contaminants, excipients, and leachants from devices used to deliver biologic products are similar to the low-dose safety assessment procedures discussed previously.
The CBER approach to risk assessment and risk management decision-making processes for biologic product approval and surveillance is similar to that of the CDER. The availability of controlled human data during the premarketing phase reduces the uncertainty of exposure and thus provides important data not only to assess the predictive value of preclinical animal data but to select the most appropriate animal model(s) to improve the extrapolation of such data.
National Center for Toxicological Research
The NCTR conducts scientific research that supports and anticipates the current and future regulatory needs of the U.S. FDA. This involves fundamental and applied research designed specifically to define biologic mechanisms of action underlying the toxicity of products regulated by the U.S. FDA. This research is aimed at understanding critical biologic events in the expression of toxicity and at developing methods to improve assessment of human exposure, susceptibility, and risk.
Toxicologic research has traditionally sought to understand basic tenets of biologic and biochemical sciences. As toxicology is evolving from a descriptive science to one based on mechanistic understanding, the hope often is expressed that mechanistic information will eventually reduce, and in some cases eliminate, uncertainty in predicting the toxicity of chemical products.
Research on mechanisms of action is generally expensive and complex. Mechanistic data on occasion can be used to discount a mode of action, but are seldom adequate to validate a mode of action.
One aspect of the NCTR program is to conduct concept-driven research that addresses longer-range regulatory needs of the U.S. FDA. For example, studies are being conducted using advanced molecular biology on carcinogenic agents that exert their effects through indirect or secondary mechanisms, dietary modulation of toxicity, and foreign body (biomaterial) carcinogenesis research to assess immune response and identify the role of oxidative DNA damage. Measurements of DNA adducts, cellular proliferation, and apoptosis are being considered for improvement of predicting cancer risk. Biologically based pharmacokinetic models are being developed to estimate doses of toxicants to fetuses during pregnancy. Knowledge of receptor mediation or saturable toxification and detoxification influences the choice of dose-response models for predicting toxicity. Gradually our knowledge of mechanisms of toxicity also is improving our ability to estimate benchmark doses (9) associated with low incidence of adverse events.
In addition to research conducted by the NCTR, a pool of scientists assists other U.S. FDA centers on specific scientific issues.
Summary
Under the federal FDCA the U.S. FDA regulates a diverse array of consumer products including food, drugs, cosmetics, animal drugs, biologics, and medical devices. The legal and regulatory standards permit the consideration of benefits for some products. Both adaptive biologic and beneficial health effects are considered when not precluded by statutes. For end points other than cancer, the emphasis is on the identification of the NOAEL and the use of safety factors to establish acceptable levels of exposure. The consideration of the biologic effects of low-level exposures to toxic substances must determine whether an effect is adverse or a normal adaptive response. For carcinogenic contaminants cancer risk at low exposure levels is generally estimated by linear extrapolation below the experimental dose range.
The U.S. FDA is conducting research on toxicologic effects to develop knowledge bases and predictive strategies for biologic effects at the low end of the dose range corresponding to human exposure levels. Because of the wide diversity of legal and regulatory standards for various consumer products regulated by the U.S. FDA, agency-wide safety and risk assessment procedures and policies generally do not exist.
